Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells

References

Page 1

	Year	Citations
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, New England Journal of Medicine	2018	3.3K
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen, The Lancet Platinum–etoposide Versus Platinum–etoposideMedicinePharmacologyImmune Checkpoint InhibitorFirst-line Treatment	2019	2.1K
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial Scott Antonia, José A. López-Martín, Johanna C. Bendell, The Lancet Oncology MedicineCheckmate 032PharmacologyImmune Checkpoint InhibitorCancer Treatment	2016	1.2K
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity Julie Vincent, Grégoire Mignot, Fanny Chalmin, Cancer Research	2010	1.2K
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy C. Marcela Díaz‐Montero, Mohamed L. Salem, Michael I. Nishimura, Cancer Immunology Immunotherapy Clinical Cancer StageTumor BiologyMedicineMetronomic TherapyImmunology	2008	1.2K
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial José Trigo, Vivek Subbiah, Benjamin Besse, The Lancet Oncology Second-line TreatmentOncologyMetronomic TherapyClinical TrialsPathology	2020	433
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín, Journal of Thoracic Oncology	2019	427
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 Neal Ready, Anna F. Farago, Filippo de Braud, Journal of Thoracic Oncology	2018	373
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice Hanh K. Le, Laura Graham, Esther Cha, International Immunopharmacology T CellsImmunologyImmune Checkpoint InhibitorTumor SuppressorBalb/c Mice	2009	362
Ibrutinib treatment improves T cell number and function in CLL patients Meixiao Long, Kyle A. Beckwith, Priscilla Do, Journal of Clinical Investigation	2017	362

Page 1